Abstract:Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases, many of which had a poor or devastating prognosis prior to the advent of immunosuppressive drugs such as systemic corticosteroids, which down-regulate the immune pathogenesis in these disorders. Glucocorticoids and adjuvant immunosuppressive drugs have been of major benefit for the fast control of most of these disorders, but their long-term use is limited by major side effects such as blood cytopenia, osteoporosis, diabetes mellitus, hypertension, and gastrointestinal ulcers. In recent years, major efforts were made to identify key elements in the pathogenesis of autoimmune bullous disorders, leading to the identification of their autoantigens, which are mainly located in desmosomes (pemphigus) and the basement membrane zone (pemphigoids). In the majority of cases, immunoglobulin G, and to a lesser extent, immunoglobulin A autoantibodies directed against distinct cutaneous adhesion molecules are directly responsible for the loss of cell-cell and cell-basement membrane adhesion, which is clinically related to the formation of blisters and/or erosions of the skin and mucous membranes. We describe and discuss novel therapeutic strategies that directly interfere with the production and regulation of pathogenic autoantibodies (rituximab), their catabolism (intravenous immunoglobulins), and their presence in the circulation and extravascular tissues such as the skin (immunoadsorption), leading to a significant amelioration of disease. Moreover, we show that these novel therapies have pleiotropic effects on various proinflammatory cells and cytokines. Recent studies in bullous pemphigoid suggest that targeting of immunoglobulin E autoantibodies (omalizumab) may be also beneficial. In summary, the introduction of targeted therapies in pemphigus and pemphigoid holds major promise because of the high efficacy and fewer side effects compared with conventional global immunosuppressive therapy.

Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches

Bullous Pemphygoid and Novel Therapeutic Approaches

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets

Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches

A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions

Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Immune cells in pemphigus vulgaris and bullous Pemphigoid: From pathogenic roles to targeting therapies

Targeted Therapies for Autoimmune Bullous Diseases: Current Status

Updates on the Management of Autoimmune Bullous Diseases

Bullous pemphigoid treatment review

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

[New aspects on the pathogenesis of bullous pemphigoid].

Bullous pemphigoid: from bench to bedside

What's new in the pathogeneses and triggering factors of bullous pemphigoid

Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update

Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Recent developments in the pathogenesis of pruritus in bullous pemphigoid

[Bullous pemphigoid: diagnostics and new therapeutic strategies]

Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein